Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

INTRODUCTION: Prophylaxis with recombinant factor VIII (rFVIII) is the current standard of care for haemophilia A. Several approaches have been used to extend the half-life of rFVIII to improve prophylaxis outcomes. An indirect comparison of pivotal clinical trial data was performed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakimi, Zalmai, Santagostino, Elena, Postma, Maarten J., Nazir, Jameel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889532/
https://www.ncbi.nlm.nih.gov/pubmed/33377987
http://dx.doi.org/10.1007/s12325-020-01599-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889532/
https://www.ncbi.nlm.nih.gov/pubmed/33377987
http://dx.doi.org/10.1007/s12325-020-01599-1

Ejemplares similares